A chance discovery in Dr. Federica del Monte's lab at the Medical University of South Carolina has unraveled a mystery that has puzzled cardiologists for years: why do misfolded protein plaques accumulate in the hearts of patients with idiopathic dilated cardiomyopathy, and what triggers the disease to silently advance until patients face heart failure?
For decades, researchers noticed something strange in diseased hearts — clusters of misfolded proteins that looked remarkably similar to those found in Alzheimer's disease. Del Monte first observed these peculiar plaques in 2010 while working on an entirely separate project, a serendipitous moment that would reshape her career. She connected her discovery to an Alzheimer's gene, establishing the first biological link between the two seemingly unrelated conditions. Now, her team has taken a crucial step forward: they've identified what goes wrong inside cells to allow these plaques to form.
Publishing their findings in the Journal of Molecular and Cellular Cardiology, the del Monte Lab discovered that the culprit lies in the cell's protein repair system — the machinery responsible for fixing or eliminating damaged proteins before they accumulate into toxic clumps. The team examined the three major branches of this repair system and found critical defects in how proteins are modified after they're made. These modifications, called post-translational modifications or PTMs, are essentially chemical switches that tell repair proteins when and how to work.
"Often it is not how much protein is present," del Monte explained, "but if the changes that activate the proteins are abnormal." Her team found that in hearts with idiopathic dilated cardiomyopathy, these PTMs were abnormally altered, disrupting the system's ability to respond when misfolded proteins trigger stress signals. As postdoctoral fellow Camilla Bacchin noted, the modifications observed in diseased hearts "were primarily causing a shift toward cell death," essentially sabotaging the heart's natural defense mechanism.
The implications extend far beyond cardiology. Because IDCM can manifest before Alzheimer's symptoms appear in the brain, the heart could serve as an early warning system. Del Monte has begun introducing heart ultrasound screenings in Alzheimer's clinics, looking for the telltale enlarged and weakened left ventricle characteristic of IDCM. This reversed approach — using cardiology to inform neurology — could catch both conditions earlier, when treatment is most likely to help.
The decade-long journey to these findings reflects scientific collaboration at its finest. Researchers who began as postdoctoral fellows in the del Monte Lab have since scattered across the globe — Marco Luciani now leads research at the University of Zurich, Luca Trocone works at Brigham and Women's Hospital in Boston, and Cristina Balla is faculty at the University of Ferrara in Italy. Yet they remained connected to the project, demonstrating how scientific questions can drive sustained partnerships across continents and institutions.
With the protein repair defect now identified, the path forward becomes clearer. Earlier detection through dual heart-brain screening and earlier intervention targeting the faulty repair system could transform outcomes for patients who might otherwise progress silently toward life-threatening heart failure. For the first time, researchers understand not just that these plaques form, but why — and that understanding opens doors to prevention.